8 research outputs found
Ribose supplementation alone or with elevated creatine does not preserve high energy nucleotides or cardiac function in the failing mouse heart
Background: Reduced levels of creatine and total adenine nucleotides (sum of ATP, ADP and AMP) are hallmarks of chronic
heart failure and restoring these pools is predicted to be beneficial by maintaining the diseased heart in a more favourable
energy state. Ribose supplementation is thought to support both salvage and re-synthesis of adenine nucleotides by
bypassing the rate-limiting step. We therefore tested whether ribose would be beneficial in chronic heart failure in control
mice and in mice with elevated myocardial creatine due to overexpression of the creatine transporter (CrT-OE).
Methods and Results: Four groups were studied: sham; myocardial infarction (MI); MI+ribose; MI+CrT-OE+ribose. In a pilot
study, ribose given in drinking water was bioavailable, resulting in a two-fold increase in myocardial ribose-5-phosphate
levels. However, 8 weeks post-surgery, total adenine nucleotide (TAN) pool was decreased to a similar amount (8–14%) in all
infarcted groups irrespective of the treatment received. All infarcted groups also presented with a similar and substantial
degree of left ventricular (LV) dysfunction (3-fold reduction in ejection fraction) and LV hypertrophy (32–47% increased
mass). Ejection fraction closely correlated with infarct size independently of treatment (r2 = 0.63, p<0.0001), but did not
correlate with myocardial creatine or TAN levels.
Conclusion: Elevating myocardial ribose and creatine levels failed to maintain TAN pool or improve post-infarction LV
remodeling and function. This suggests that ribose is not rate-limiting for purine nucleotide biosynthesis in the chronically
failing mouse heart and that alternative strategies to preserve TAN pool should be investigated
Myocardial creatine levels do not influence response to acute oxidative stress in isolated perfused heart
Background: Multiple studies suggest creatine mediates anti-oxidant activity in addition to its established role in cellular
energy metabolism. The functional significance for the heart has yet to be established, but antioxidant activity could
contribute to the cardioprotective effect of creatine in ischaemia/reperfusion injury.
Objectives: To determine whether intracellular creatine levels influence responses to acute reactive oxygen species (ROS)
exposure in the intact beating heart. We hypothesised that mice with elevated creatine due to over-expression of the
creatine transporter (CrT-OE) would be relatively protected, while mice with creatine-deficiency (GAMT KO) would fare
worse.
Methods and Results: CrT-OE mice were pre-selected for creatine levels 20–100% above wild-type using in vivo 1
H–
MRS.
Hearts were perfused in isovolumic Langendorff mode and cardiac function monitored throughout. After 20 min
equilibration, hearts were perfused with either H2O2 0.5 mM (30 min), or the anti-neoplastic drug doxorubicin 15 mM
(100 min). Protein carbonylation, creatine kinase isoenzyme activities and phospho-PKCd expression were quantified in
perfused hearts as markers of oxidative damage and apoptotic signalling. Wild-type hearts responded to ROS challenge
with a profound decline in contractile function that was ameliorated by co-administration of catalase or dexrazoxane as
positive controls. In contrast, the functional deterioration in CrT-OE and GAMT KO hearts was indistinguishable from wildtype
controls, as was the extent of oxidative damage and apoptosis. Exogenous creatine supplementation also failed to
protect hearts from doxorubicin-induced dysfunction.
Conclusions: Intracellular creatine levels do not influence the response to acute ROS challenge in the intact beating heart,
arguing against creatine exerting (patho-)physiologically relevant anti-oxidant activity
The Chihuahua dog: A new animal model for neuronal ceroid lipofuscinosis CLN7 disease?
Neuronal ceroid lipofuscinoses (NCLs) are a group of incurable lysosomal storage disorders characterized by neurodegeneration and accumulation of lipopigments mainly within the neurons. We studied two littermate Chihuahua dogs presenting with progressive signs of blindness, ataxia, pacing, and cognitive impairment from 1 year of age. Because of worsening of clinical signs, both dogs were euthanized at about 2 years of age. Postmortem examination revealed marked accumulation of autofluorescent intracellular inclusions within the brain, characteristic of NCL. Whole-genome sequencing was performed on one of the affected dogs. After sequence alignment and variant calling against the canine reference genome, variants were identified in the coding region or splicing regions of four previously known NCL genes (CLN6, ARSG, CLN2 [=TPP1], and CLN7 [=MFSD8]). Subsequent segregation analysis within the family (two affected dogs, both parents, and three relatives) identified MFSD8:p.Phe282Leufs13*, which had previously been identified in one Chinese crested dog with no available ancestries, as the causal mutation. Because of the similarities of the clinical signs and histopathological changes with the human form of the disease, we propose that the Chihuahua dog could be a good animal model of CLN7 disease
A SCN9A variant in a family of mixed breed dogs with congenital insensitivity to pain
BACKGROUND
Congenital insensitivity to pain (CIP) and hereditary sensory and autonomic neuropathies (HSANs) are a rare group of genetic disorders causing inability to feel pain. Three different associated variants have been identified in dogs: 1 in Border Collies, 1 in mixed breed dogs, and 1 in Spaniels and Pointers.
OBJECTIVES
To clinically and genetically characterize CIP in a family of mixed breed dogs.
ANIMALS
Two mixed breed dogs from the same litter were independently presented: 1 for evaluation of painless fractures, and the other for chronic thermal skin injuries.
METHODS
Physical, neurological, and histopathological evaluations were performed. Whole genome sequencing of 1 affected dog was used to identify homozygous protein-changing variants that were not present in 926 control genomes from diverse dog breeds.
RESULTS
Physical and neurological examinations showed the absence of superficial and deep pain perception in the entire body. Histopathological evaluations of the brain, spinal cord and sensory ganglia were normal. Whole genome sequencing identified a homozygous missense variant in SCN9A, XM_038584713.1:c.2761C>T or XP_038440641.1:(p.Arg921Cys). Both affected dogs were homozygous for the mutant allele, which was not detected in 926 dogs of different breeds.
CONCLUSIONS AND CLINICAL IMPORTANCE
We confirmed the diagnosis of CIP in a family of mixed breed dogs and identified a likely pathogenic variant in the SCN9A gene. The clinical signs observed in these dogs mimic those reported in humans with pathogenic SCN9A variants causing CIP. This report is the first of a spontaneous pathogenic SCN9A variant in domestic animals
The neuronal ceroid lipofuscinoses: opportunities from model systems
The neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, generally with childhood onset. Despite the fact that these diseases remain fatal, significant breakthroughs have been made in our understanding of the genetics that underpin these conditions. This understanding has allowed the development of a broad range of models to study disease processes, and to develop new therapeutic approaches. Such models have contributed significantly to our knowledge of these conditions. In this review we will focus on the advantages of each individual model, describe some of the contributions the models have made to our understanding of the broader disease biology and highlight new techniques and approaches relevant to the study and potential treatment of the neuronal ceroid lipofuscinoses. This article is part of a Special Issue entitled: "Current Research on the Neuronal Ceroid Lipofuscinoses (Batten Disease)"
Recommended from our members
A TNR Frameshift Variant in Weimaraner Dogs with an Exercise‐Induced Paroxysmal Movement Disorder
Background: Some paroxysmal movement disorders remain without an identified genetic cause. Objectives: The aim was to identify the causal genetic variant for a paroxysmal dystonia–ataxia syndrome in Weimaraner dogs. Methods: Clinical and diagnostic investigations were performed. Whole genome sequencing of one affected dog was used to identify private homozygous variants against 921 control genomes. Results: Four Weimaraners were presented for episodes of abnormal gait. Results of examinations and diagnostic investigations were unremarkable. Whole genome sequencing revealed a private frameshift variant in the TNR (tenascin‐R) gene in an affected dog, XM_038542431.1:c.831dupC, which is predicted to truncate more than 75% of the open read frame. Genotypes in a cohort of 4 affected and 70 unaffected Weimaraners showed perfect association with the disease phenotype. Conclusions: We report the association of a TNR variant with a paroxysmal dystonia–ataxia syndrome in Weimaraners. It might be relevant to include sequencing of this gene in diagnosing humans with unexplained paroxysmal movement disorders. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society